BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2020

View Archived Issues

Base editor targets mitochondrial DNA

Read More

KPG-121, a cereblon modulator, shows promising antitumor activity in vitro and in vivo

Read More

Recombinant Bifidobacterium longum APS-002 secretes T-cell-redirecting diabody DBERB1

Read More

Metagenomic data aid phage therapy development

Read More

Discovery of KB-00130742 as orally bioavailable and ultra-selective inhibitor of CDK9

Read More

CCX-6569 shows promising antitumor activity in model of colon adenocarcinoma

Read More

Huihan Medical Technologies discloses new Wnt signaling inhibitors

Read More

Merck & Co. describes new anti-HIV compounds

Read More

New bacterial DNA gyrase/DNA topoisomerase IV inhibitors discovered at Roche

Read More

PharmaBlock Sciences identifies influenza virus replication inhibitors

Read More

Novel SSTR antagonist [177Lu]DOTA-LM3 shows promising results in patients with NENs

Read More

Novartis patents mutant CFTR correctors

Read More

Positive preclinical data for AdCOVID intranasal COVID-19 vaccine candidate

Read More

New sulfonamide derivatives as potent, selective and state-dependent Nav1.7 inhibitors for pain

Read More

BAN-2401 to be evaluated in new phase III AHEAD 3-45 program

Read More

Shanghai Junshi and Revitope enter into research collaboration and license agreement

Read More

Results of a phase III trial of reltecimod in severe necrotizing soft tissue infections

Read More

Dewpoint and Merck & Co. collaborate to develop condensate-based drug candidates against HIV

Read More

Interim phase I data presented for CTT-1403 in mCRPC

Read More

MHRA grants early access to lumasiran in the U.K.

Read More

INmune Bio reports interim phase Ib data on XPro-1595 in Alzheimer's disease

Read More

First patient dosed in OLE/switch study of FT-218 in narcolepsy

Read More

Immunomedics and Roche expand collaboration to study Trodelvy with Tecentriq

Read More

Innovation Pharmaceuticals provides updates regarding clinical testing of brilacidin in COVID-19

Read More

Arcutis begins phase IIb portion of phase I/IIb study of ARQ-252 for chronic hand eczema

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing